collagen diseases, kidney diseases, digestive diaseases, liver diaseases, neurological diseases, kidney transplant patients
Conditions
Interventions
Sponsors
Department of Pediatrics, Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Equal or more than one years old. 2. Patients under treatment with immunosuppressants(tacrolimus, cyclosporine, mizoribine, azathioprine, methotrexate mycophenolate mofetil) 3. Normal cellular immunity (CD4 counts>500/mm3, PHA lymphocyte stimulatory test-stimulation index>101.6). 4. Serum IgG level>300mg/dl 5. Negative or borderline antibody titer of one or more of the following viruses: measles, rubella, varicella, or mumps. 6. Patients under treatment with prednisolone <1mg/kg/day or <2mg/kg every alternate day. 7. tacrolimus trough level<10ng/ml or cyclosporine trough level<100ng/ml. 8. Patients with low activity of underlying disease. 9. Patients who cannot discontinue immunosuppressants because of primary disease.
Exclusion criteria
Exclusion criteria: 1. Steroid use of more than 1mg/kg/d. 2. For renal transplant recipients, <1 year since transplantation or acute rejection within the previous 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Assessment of antibody acquisition after vaccination classified by each virus. 2) Analysis of long maintenance of acquired immunity. 3) Analysis of incididence of adverse events. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Analysis of causes of vaccine failure. 2) Analysis of causes of adverse events. 3) Analysis of effect for prevention of virus infection. | — |
Countries
Japan
Contacts
Public ContactKenichi Nishimura
Yokohama City University Department of Pediatrics
Outcome results
None listed